Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its participation in three major healthcare investor conferences in September 2025.
The company will present at the Citi's 2025 Biopharma Back to School Conference (September 2), the Cantor Global Healthcare Conference (September 3), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 10). All presentations will be accessible via webcast on the company's website.
Zenas BioPharma (NASDAQ:ZBIO), una società biofarmaceutica in fase clinica focalizzata su terapie per le malattie autoimmuni, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario a settembre 2025.
La società presenterà alla Citi's 2025 Biopharma Back to School Conference (2 settembre), alla Cantor Global Healthcare Conference (3 settembre) e alla Morgan Stanley 23rd Annual Global Healthcare Conference (10 settembre). Tutte le presentazioni saranno disponibili in webcast sul sito web della società.
Zenas BioPharma (NASDAQ:ZBIO), una compañía biofarmacéutica en fase clínica centrada en terapias para enfermedades autoinmunes, ha anunciado su participación en tres importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La compañía realizará presentaciones en la Citi's 2025 Biopharma Back to School Conference (2 de septiembre), en la Cantor Global Healthcare Conference (3 de septiembre) y en la Morgan Stanley 23rd Annual Global Healthcare Conference (10 de septiembre). Todas las presentaciones estarán disponibles por webcast en la página web de la compañía.
Zenas BioPharma (NASDAQ:ZBIO)는 자가면역 질환 치료제에 주력하는 임상 단계의 바이오제약사로, 2025년 9월에 열리는 주요 의료 투자자 콘퍼런스 3곳에 참여한다고 발표했습니다.
회사는 Citi's 2025 Biopharma Back to School Conference (9월 2일), Cantor Global Healthcare Conference (9월 3일), Morgan Stanley 23rd Annual Global Healthcare Conference (9월 10일)에서 발표할 예정입니다. 모든 발표는 회사 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Zenas BioPharma (NASDAQ:ZBIO), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies des maladies auto-immunes, a annoncé sa participation à trois grandes conférences pour investisseurs du secteur de la santé en septembre 2025.
L'entreprise présentera lors de la Citi's 2025 Biopharma Back to School Conference (2 septembre), de la Cantor Global Healthcare Conference (3 septembre) et de la Morgan Stanley 23rd Annual Global Healthcare Conference (10 septembre). Toutes les présentations seront accessibles en webcast sur le site web de la société.
Zenas BioPharma (NASDAQ:ZBIO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Therapien für Autoimmunerkrankungen, hat seine Teilnahme an drei wichtigen Healthcare-Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird auf der Citi's 2025 Biopharma Back to School Conference (2. September), der Cantor Global Healthcare Conference (3. September) und der Morgan Stanley 23rd Annual Global Healthcare Conference (10. September) präsentieren. Alle Präsentationen werden per Webcast auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management’s presentations at the following investor conferences in September:
- Citi's 2025 Biopharma Back to School Conference on Tuesday, September 2, 2025, at 1:00 p.m. ET
- Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 8:35 a.m. ET
- Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET
Live webcasts and archived replays of the Company’s presentations can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
FAQ
When is Zenas BioPharma (ZBIO) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Zenas BioPharma's (ZBIO) conference presentations in September 2025?
Which investor conferences will Zenas BioPharma (ZBIO) attend in September 2025?
What is Zenas BioPharma's (ZBIO) main business focus?
